IDEAS home Printed from https://ideas.repec.org/a/sae/anjomc/v19y2022i2p141-151.html
   My bibliography  Save this article

ICU Pharma Pakistan: Growth Crossroads

Author

Listed:
  • Sami Ullah Bajwa
  • Adeel S. Shaikh
  • Muhammad Umer Azeem
  • Khuram Shahzad
  • Naveda Kitchlew

Abstract

Growth from a small-scale venture to a medium-sized company entails different challenges and strategies to tackle them. This case provides an account of one such company operating in the pharmaceutical sector of Pakistan. International Collaborated Unit Pharma (ICU Pharma) started in 2005 in the small town of Dera Ghazi Khan, in the province of Punjab, as a distributor of Ferozsons (Private) Ltd, a leading pharmaceutical manufacturer in Pakistan. Going through various phases of growth and strategic shifts, it had become a well-established company by 2019, with PKR 200 million net worth and a sales network covering thirty-four districts in Punjab, Khyber Pakhtunkhwa and Sindh provinces. In 2018, the company faced a growth dilemma when, despite the growing demand for its products, it had to curtail sales growth and divert resources towards building a manufacturing facility in Lahore. This case illustrates how industry growth, country-level initiatives for the implementation of Sustainable Development Goals on Health (SDG No. 3), policies of the Drug Regulation Authority of Pakistan (DRAP), weak contract enforcement in Pakistan and threats from suppliers, along with other external forces, constrained a company’s decision to opt for a backward integration strategy instead of going for the more plausible strategy of product and market development.

Suggested Citation

  • Sami Ullah Bajwa & Adeel S. Shaikh & Muhammad Umer Azeem & Khuram Shahzad & Naveda Kitchlew, 2022. "ICU Pharma Pakistan: Growth Crossroads," Asian Journal of Management Cases, , vol. 19(2), pages 141-151, September.
    • Handle: RePEc:sae:anjomc:v:19:y:2022:i:2:p:141-151
    DOI: 10.1177/0972820120956947
    as

    Download full text from publisher

    File URL: https://journals.sagepub.com/doi/10.1177/0972820120956947
    Download Restriction: no
    File URL: https://libkey.io/10.1177/0972820120956947?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:anjomc:v:19:y:2022:i:2:p:141-151. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.